Abstract:There is increasing interest in Alzheimer's disease related plasma biomarkers due to their accessibility and scalability. We hypothesized that integrating plasma biomarkers with other commonly used and available participant data (MRI, cardiovascular factors, lifestyle, genetics) using machine learning (ML) models can improve individual prediction of cognitive outcomes. Further, our goal was to evaluate the heterogeneity of these predictors across different age strata. This longitudinal study included 1185 participants from the Mayo Clinic Study of Aging who had complete plasma analyte work-up at baseline. We used the Quanterix Simoa immunoassay to measure neurofilament light, Aβ1-42 and Aβ1-40 (used as Aβ42/Aβ40 ratio), glial fibrillary acidic protein, and phosphorylated tau 181 (p-tau181). Participants' brain health was evaluated through gray and white matter structural MRIs. The study also considered cardiovascular factors (hyperlipidemia, hypertension, stroke, diabetes, chronic kidney disease), lifestyle factors (area deprivation index, body mass index, cognitive and physical activities), and genetic factors (APOE, single nucleotide polymorphisms, and polygenic risk scores). An ML model was developed to predict cognitive outcomes at baseline and decline (slope). Three models were created: a base model with groups of risk factors as predictors, an enhanced model included socio-demographics, and a final enhanced model by incorporating plasma and socio-demographics into the base models. Models were explained for three age strata: younger than 65 years, 65-80 years, and older than 80 years, and further divided based on amyloid positivity status. Regardless of amyloid status the plasma biomarkers showed comparable performance (R² = 0.15) to MRI (R² = 0.18) and cardiovascular measures (R² = 0.10) when predicting cognitive decline. Inclusion of cardiovascular or MRI measures with plasma in the presence of socio-demographic improved cognitive decline prediction (R² = 0.26 and 0.27). For amyloid positive individuals Aβ42/Aβ40, glial fibrillary acidic protein and p-tau181 were the top predictors of cognitive decline while Aβ42/Aβ40 was prominent for amyloid negative participants across all age groups. Socio-demographics explained a large portion of the variance in the amyloid negative individuals while the plasma biomarkers predominantly explained the variance in amyloid positive individuals (21% to 37% from the younger to the older age group). Plasma biomarkers performed similarly to MRI and cardiovascular measures when predicting cognitive outcomes and combining them with either measure resulted in better performance. Top predictors were heterogeneous between cross-sectional and longitudinal cognition models, across age groups, and amyloid status. Multimodal approaches will enhance the usefulness of plasma biomarkers through careful considerations of a study population's socio-demographics, brain and cardiovascular health.

Shared plasma metabolomic profiles of cognitive and mobility decline predict future dementia

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults

Circulating Metabolome in Relation to Cognitive Impairment: a Community-Based Cohort of Older Adults

Plasma metabolic profiles predict future dementia and dementia subtypes: a prospective analysis of 274,160 participants

Plasma metabolomic markers underlying skeletal muscle mitochondrial function relationships with cognition and motor function

Circulating Metabolites and Risk of Incident Dementia: A Prospective Cohort Study.

Peripheral Serum Metabolomic Profiles Inform Central Cognitive Impairment

Plasma metabolomic signature of healthy lifestyle, structural brain reserve and risk of dementia

Presymptomatic Profiles of Cognitive Impairment With Prior Mobility Impairment

The blood metabolome of cognitive function and brain health in middle-aged adults — influences of genes, gut microbiome, and exposome

Plasma metabolomics and lipidomics signatures of motoric cognitive risk syndrome in community-dwelling older adults

Metabolomics in the Development and Progression of Dementia: A Systematic Review

Large-scale plasma proteomic analysis identifies proteins and pathways associated with dementia risk

Circulating Lipoproteins Mediate the Association Between Cardiovascular Risk Factors and Cognitive Decline: A Community-Based Cohort Study

Can integration of Alzheimer's plasma biomarkers with MRI, cardiovascular, genetics, and lifestyle measures improve cognition prediction?

Metabolomics And Incident Dementia In Older Chinese Adults: The Shanghai Aging Study

Association of Multiple Metabolic and Cardiovascular Markers with the Risk of Cognitive Decline and Mortality in Adults with Alzheimer’s Disease and AD-related Dementia or Cognitive Decline: a Prospective Cohort Study

Plasma Proteomic Profiles Predict Future Dementia in Healthy Adults

Association of multiple metabolic and cardiovascular markers with the risk of cognitive decline and mortality in adults with Alzheimer's disease and AD-related dementia or cognitive decline: a prospective cohort study

Plasma metabolomic profiles of dementia: a prospective study of 110,655 participants in the UK Biobank